(Q40481513)

English

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

0 references

0 references

1 reference

ChEBI release 2020-05-28

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Christine Katlama

3

object named as

Christine Katlama

0 references

10

object named as

Chloe Orkin

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jürgen Rockstroh

1

object named as

Jürgen K Rockstroh

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8

object named as

Michael S Saag

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

19

object named as

Mark Sulkowski

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

4

object named as

Jay Lalezari

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Mark Nelson

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Josep Mallolas

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Mark Bloch

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gail V Matthews

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Philippe J Zamor

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jacqueline Gress

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Stephanie Klopfer

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Melissa Shaughnessy

13

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Janice Wahl

14

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Bach-Yen T Nguyen

15

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Eliav Barr

16

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Heather L Platt

17

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Michael N Robertson

18

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

9 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The lancet. HIV

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

e319-27

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Viral hepatitis in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV and viral hepatitis coinfections: advances and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Deaths among people with hepatitis C in New York City, 2000-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Global epidemiology and genotype distribution of the hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2815%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3018(15)00114-9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40481513&oldid=2120313781"